Cytoxan

(redirected from cyclophosphamide)
Also found in: Dictionary, Medical, Acronyms, Wikipedia.
Related to cyclophosphamide: vincristine

Cytoxan

(sītŏk`sĭn), trade name for the drug cyclophosphamide, used to inhibit growth of tumors and rapidly proliferating cells. It is used in the treatment of leukemia, Hodgkin's disease, and lymphosarcoma and other solid tumors. A drug of great specificity, Cytoxan is activated in the body by the enzymes in certain types of tumors. Because it is also activated in such tissues as blood plasma and liver, it is a highly toxic substance. Nevertheless, it is a potent and useful chemotherapeutic agent.
References in periodicals archive ?
Results of the phase 2 study, published in the New England Journal of Medicine, found that the intention-to-treat population global rank composite score favored transplantation over cyclophosphamide in 67% of 1,404 pairwise comparisons at 54 months (P = .
The clinical trial, called Scleroderma: Cyclophosphamide or Transplantation (SCOT), compared the safety and potential benefits of the two treatment regimens among 75 people with diffuse systemic sclerosis who had lung or kidney involvement.
No one in the cyclophosphamide group died from the treatment.
Effect of colchicine was evaluated by performing delayed type hypersensitivity, macrophage engulfment assay, detection of nitric oxide (NO) productionand cyclophosphamide induced neutropenia assay.
Keywords: Anti-mullerian hormone, Chemotherapy, a-tocopherol, Ovarian reserve, Cyclophosphamide.
Phase I and II involved slow intravenous infusion (Over 2 - 3 hours) of dexamethasone 100 mg (Suprapharmacological dose) in 500 mL of 5% dextrose on 3 consecutive days and 500 mg cyclophosphamide on 2nd day of the pulse and such pulses were repeated every 28 days.
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: A phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Although prospective randomized control studies are lacking, current evidence suggests that steroids and cyclophosphamide should be used as first-line agents.
Cyclophosphamide is an alkylating chemotherapeutic agent that prevents cell meiosis by causing errors in the cell's DNA.
The case presented described the development of acute pancreatitis in a patient with breast cancer three days after receiving the chemotherapy regimen consisting of cyclophosphamide and doxorubicin.
The primary endpoint of the study was the safety and tolerability of cyclophosphamide.
Thus, this study aimed to investigate the chlorophyllin, as well as its effects against the morphophysiological damage caused by exposure to cyclophosphamide during embryonic development, through the evaluation of congenital malformations and reproductive parameters of females.